Genomic profiling for targeted treatment in patients with incurable cancer
Official title: Proseq Cancer: A Prospective Study of Comprehensive Genomic Profiling in Patients With Incurable Cancer in Search for Targeted Treatment
Run by Aalborg University Hospital · NCT05695638 · Data updated 2026-11-12
This study is testing if using genetic information from tumors can help find better treatment options for people with incurable cancer.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 3000 (estimated) |
| Sponsor | Aalborg University Hospital Academic / other |
| Locations | 1 site (Aalborg) |
| Status | Recruiting |
| Started | July 1, 2020 |
| Main results expected | May 31, 2030 |
| Study ends | May 31, 2035 |
| Registry record updated | January 31, 2024 |
| Trial ID | NCT05695638 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults with incurable, progressing, and life-threatening cancers who have no efficient remaining standard treatment options.
✕Probably not a fit
Patients with a WHO Performance Status greater than 2 or significant comorbidities may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Proseq Cancer is a precision medicine program that utilizes whole exome sequencing (WES) and RNA sequencing to identify potential targeted treatments for patients with incurable and progressing cancers. Patients are recruited from the North Denmark Region and undergo clinical-pathological assessments, including biopsies from tumor lesions. The program allows for biobanking and sharing of genomic data while adhering to GDPR regulations. Treatment options may include nationally approved drugs or clinical protocols based on the findings from the National Tumor Board.
Why it matters
Potential benefit: If successful, this program could provide personalized treatment options for patients with limited standard treatment alternatives.
How similar studies have gone: Other studies utilizing genomic profiling for targeted treatments have shown promise, indicating that this approach is gaining traction in precision medicine.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Incurable, progressing and/or life-threatening cancer * Expected residual survival of at least 3 months * No efficient remaining standard treatment options * Patient recruited from the Region of Northern Jutland, Denmark Exclusion Criteria: * WHO Performance Status \>2 * Significant comorbidity, concurrent medication or laboratory values imposing an unacceptable risk at medical oncological treatment
Where it's running
-
Department of Oncology, Aalborg University Hospital
Aalborg, Denmark Recruiting
Study contacts
- Principal investigator: Morten Ladekarl, MD, DMSCi — Department of Oncology, Aalborg University Hospital, Denmark
- Study coordinator: Morten Ladekarl, MD, DMSci
- Email: morten.ladekarl@rn.dk
- Phone: +45 97660545
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Dabrafenib and trametinib for rare cancers with BRAF V600 mutations
This arm tests whether dabrafenib and trametinib can help adults, children, and teens with cancers that have a BRAF V600 mutation.
-
Capmatinib treatment for adults with cancers having MET gene changes
This study is testing if capmatinib, a drug for lung cancer, can help adults with different types of cancers that have changes in the MET gene.
-
Evaluating AD1208 for advanced solid tumors
This study is testing a new drug called AD1208 to see if it is safe and tolerable for people with advanced solid tumors.
-
Testing LXP1788 Injection for Advanced Solid Tumors
This study is testing a new injection called LXP1788 to see if it can safely help people with advanced solid tumors that haven't responded to other treatments.
-
Home management program for patients with blood cancers after chemotherapy
This study tests a new home care program for patients with blood cancers after high-dose chemotherapy to see if it helps them recover better while allowing them to leave the hospital sooner.
-
Pharmacogenomics to improve voriconazole dosing for fungal infections
This trial will test whether using a patient's CYP2C19 genotype with Bayesian dosing software helps get voriconazole levels into the therapeutic range by Day 8 for people with fungal infections, including those with blood cancers.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.